Trump’s Tariff Threat Spotlights Drugmakers’ US Factory Progress

President Donald Trump’s plan to impose a 100% tariff on branded and patented drugs could sharply raise costs for pharmaceutical companies without US manufacturing capacity, raising pressure on firms that have yet to break ground.

The move threatens to double the cost of global pharma’s blockbuster treatments ranging from cancer immunotherapies to weight-loss shots if construction doesn’t begin by the Oct. 1 deadline. Companies including Novartis AGand Sanofi SA have announced large US investments, though it isn’t clear from public disclosures how far those projects have progressed.

Read more: Trump Plans New Tariff Push With 100% Rate on ...